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Parasites of the genus Leishmania are intracellular proto-
zoa which are transmitted to their mammalian host by
the bite of infected sand flies and cause a group of dis-
eases known as Leishmaniasis. Despite attempting differ-
ent vaccination strategies, no human vaccine is yet
available against this disease. There is increasing evidence
that presence of a small number of live parasites is neces-
sary to maintain durable immunity, and the only way to
meet this requirement is by using attenuated live vaccines
[1]. The main obstacle about attenuated live strains is the
risk of reversion of the organism to its virulent state.
Another approach to reach this strategy is to use non-
pathogenic Leishmania such as L. tarentolae. This para-
site is lizard parasite and has never been found associated
with any leishmaniasis in humans and is considered as
non-pathogenic to humans. Previous studies have shown
that L. tarentolae can be used as a live vaccine against
L. donovani and elicit a protective Th1 immune response
[2]. Recently, by comparative genomic analysis and
expression profiles of well-characterized virulence factors
such as GP63, CPB, LPG3, Amastin and A2 between
pathogenic Leishmania species (e.g. L. major, L. infantum
and L. braziliensis) and non pathogenic L. tarentolae
revealed that only A2 is absent at the level of DNA [3].
Ar e c o m b i n a n tL. tarentolae expressing the A2 protein
was generated and its potential as a live vaccine against
L. infantum infection in BALB/c mice was examined [4].
The A2 expressing recombinant parasites showed higher
macrophage infectivity in comparison to L. tarentolae
used as a control. Immunization (i.v. and i.p.) of BALB/c
mice with recombinant L. tarentolae A2 elicited a strong
protective immunity against virulent L. infantum chal-
lenge, manifested by a dramatic decrease in parasite
burdens in the liver and the spleen of immunized mice.
I F N - gp r o d u c t i o nu p o na n t i g en stimulation indicated
that protection is associated with a Th1 cell-mediated
immunity accompanied by reduced levels of IL-5 produc-
tion (the Th2 type response). Interestingly, although
IFN-g production is also induced in groups of mice
immunized with wild type L. tarentolae, cytokine levels
are increased in the group immunized with the recombi-
nant L. tarentolae A2 and especially when the vaccine
regimen is administered via the i.p. route [4]. In conti-
nuation of these promising results, we are expanded this
idea against L. major infection as a novel vaccine regimen
by including two immunogenic parasite proteins
(cysteine proteinases A and B, CPA/CPB).
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